Karen English
Overview
Explore the profile of Karen English including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rolandsson Enes S, Dzneladze I, Hampton T, Neff S, Asarian L, Barua J, et al.
Cytotherapy
. 2025 Feb;
PMID: 39945694
The acute respiratory distress syndrome (ARDS) inflammatory environment alters mesenchymal stromal cell (MSC) gene and protein expression but effects on microRNA (miRNA) content of MSC-extracellular vesicle (EVs) remain unknown. To...
2.
Le Blanc K, Dazzi F, English K, Farge D, Galipeau J, Horwitz E, et al.
Cytotherapy
. 2025 Jan;
PMID: 39864015
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought...
3.
Bitterlich L, Tunstead C, Hogan A, Ankrum J, English K
Cytotherapy
. 2024 Nov;
27(2):169-180.
PMID: 39580716
Innate training of macrophages can be beneficial for the clearance of pathogens. However, for certain chronic conditions, innate training can have detrimental effects due to an excessive production of pro-inflammatory...
4.
Dunbar H, Hawthorne I, Tunstead C, Dunlop M, Volkova E, Weiss D, et al.
Eur J Immunol
. 2024 Nov;
55(1):e202451205.
PMID: 39502000
Enhancing mesenchymal stromal cell (MSC) therapeutic efficacy through licensing with proinflammatory cytokines is now well established. We have previously shown that macrophage migration inhibitory factor (MIF)-licensed MSCs exerted significantly enhanced...
5.
Tunstead C, Volkova E, Dunbar H, Hawthorne I, Bell A, Crowe L, et al.
Mol Ther
. 2024 Aug;
32(10):3422-3432.
PMID: 39108095
Clinical trials investigating the potential of mesenchymal stromal cells (MSCs) for the treatment of inflammatory diseases, such as acute respiratory distress syndrome (ARDS), have been disappointing, with less than 50%...
6.
Dunbar H, Hawthorne I, English K
Mol Ther
. 2024 Jun;
32(7):2047-2049.
PMID: 38906151
No abstract available.
7.
Dunbar H, Hawthorne I, Tunstead C, McNamee E, Weiss D, Armstrong M, et al.
Cytotherapy
. 2024 May;
26(10):1245-1251.
PMID: 38819366
Background: Trained immunity results in long-term immunological memory, provoking a faster and greater immune response when innate immune cells encounter a secondary, often heterologous, stimulus. We have previously shown that...
8.
Dunbar H, Hawthorne I, English K
Thorax
. 2024 Apr;
79(8):698-699.
PMID: 38575316
No abstract available.
9.
Dunbar H, Hawthorne I, McNamee E, Armstrong M, Donnelly S, English K
FASEB J
. 2024 Mar;
38(6):e23576.
PMID: 38530238
High level expression of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) has been associated with severe asthma. The role of MIF and its functional promotor polymorphism in innate immune...
10.
Santos C, Lopes-Pacheco M, English K, Rolandsson Enes S, Krasnodembskaya A, Rocco P
Cells
. 2024 Jan;
13(2).
PMID: 38247814
Mesenchymal stromal cells (MSCs) and MSC-derived extracellular vesicles (EVs) have emerged as innovative therapeutic agents for the treatment of sepsis and acute respiratory distress syndrome (ARDS). Although their potential remains...